Overview

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Status:
Active, not recruiting

Trial end date:
2026-10-10

Target enrollment:

Participant gender:

Summary

This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery (resected). Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Phase:

Phase 3

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Erlotinib Hydrochloride